Update: July 2, 2012. Glaxo Smith Kline has agreed to pay $3 billion to settle the largest health care fraud case ever. Other payments that the pharmaceutical giant made after this February 2012 post: $1500 from its political action committee to Scott Brown’s reelection campaign.
Press release yesterday from U.S. Attorney’s Office in Boston announcing recoveries in health care fraud cases, including $701 million from Abbott Laboratories for a scheme to inflate drug prices that are used by federal health care programs in setting payment rates, and $600 million from GlaxoSmithKline for distribution of adulterated drugs made in Puerto Rico.
And for Abbott, this is not the first time. A year ago, the company settled a lawsuit brought by 22 states, including Massachusetts, charging the company with deceptive trade practices in its efforts to block access to generic drugs.
No press release (yet) from campaign office of Scott Brown announcing plans to return $6500 to Abbott and $2500 to GlaxoSmithKline in campaign funds received so far this election cycle. But you’d think that a Senator who sponsored the Improper Payments Elimination and Recovery Improvement Act of 2011, to “intensify efforts to identify, prevent, and recover payment error, waste, fraud, and abuse within Federal spending” might see the connection.